Association of COMT Val158Met polymorphism and breast cancer risk: an updated meta-analysis
- Equal contributors
1 Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi, China
2 Department of Obstetrics and Gynecology and Reproductive center, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
3 Department of Occupational Health and Environmental Health, School of Public Health at Guangxi Medical University, Nanning, Guangxi, China
4 Department of Orthopedic Trauma Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi, China
5 Department of Clinical Laboratory, Baise City People's Hospital, Baise, Guangxi, China
Citation and License
Diagnostic Pathology 2012, 7:136 doi:10.1186/1746-1596-7-136Published: 8 October 2012
Catechol-O-methyltransferase (COMT) is one of the most important enzymes involved in estrogen metabolism and its functional genetic polymorphisms may be associated with breast cancer (BC) risk. Many epidemiological studies have been conducted to explore the association between the COMT Val158Met polymorphism and breast cancer risk. However, the results remain inconclusive. In order to derive a more precise estimation of this relationship, a large meta-analysis was performed in this study.
Systematic searches of the PubMed, Embase and Cochrane Library were performed. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to estimate the strength of the association.
A total of 56 studies including 34,358 breast cancer cases and 45,429 controls were included. Overall, no significant associations between the COMT Val158Met polymorphism and breast cancer risk were found for LL versus HH, HL versus HH, LL versus HL, recessive model LL versus HL+HH, and dominant model LL+HL versus HH. In subgroup analysis by ethnicity, source of controls, and menopausal status, there was still no significant association detected in any of the genetic models.
Our meta-analysis results suggest that the COMT Val158Met polymorphism may not contribute to breast cancer susceptibility.
The virtual slides(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs4806123577708417 webcite